Cargando…

Highly synergistic drug combination prevents vaginal HIV infection in humanized mice

The HIV-1 epidemic remains an urgent global health concern. Young women are disproportionately at risk of acquiring the virus. A range of highly effective, female-controlled, discrete vaginal products therefore is needed to help curb the epidemic. Oral tenofovir disoproxil fumarate (TDF) and emtrici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baum, Marc M., Ramirez, Christina M., Moss, John A., Gunawardana, Manjula, Bobardt, Michael, Gallay, Philippe A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400648/ https://www.ncbi.nlm.nih.gov/pubmed/32747682 http://dx.doi.org/10.1038/s41598-020-69937-5

Ejemplares similares

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice
por: Gallay, Philippe A., et al.
Publicado: (2017)

Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice
por: Gallay, Philippe A., et al.
Publicado: (2023)

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance
por: Bobardt, Michael, et al.
Publicado: (2021)

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice
por: Gallay, Philippe A., et al.
Publicado: (2018)

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc
por: Vincent, Kathleen Listiak, et al.
Publicado: (2018)

Global Expression of Molecular Transporters in the Human Vaginal Tract: Implications for HIV Chemoprophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2013)

Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2022)

Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study
por: Gunawardana, Manjula, et al.
Publicado: (2022)

The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020)

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
por: Bobardt, Michael, et al.
Publicado: (2014)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2020)

Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices
por: Gunaseelan, Simi, et al.
Publicado: (2012)

Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model
por: Smith, James M., et al.
Publicado: (2017)

Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2022)

Erratum to: Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices
por: Gunaseelan, Simi, et al.
Publicado: (2012)

Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms
por: Gallay, Philippe A., et al.
Publicado: (2013)

Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
por: Bobardt, Michael, et al.
Publicado: (2020)

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
por: Gallay, Philippe, et al.
Publicado: (2019)

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019)

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
por: Gallay, Philippe A., et al.
Publicado: (2015)

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection
por: Chatterji, Udayan, et al.
Publicado: (2016)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
por: Stauffer, Winston, et al.
Publicado: (2023)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
por: Stauffer, Winston, et al.
Publicado: (2023)

Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice
por: Paull, Jeremy R. A., et al.
Publicado: (2021)

Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial
por: Vincent, Kathleen L., et al.
Publicado: (2018)

Concentrative Nucleoside Transporter 3 Is Located on Microvilli of Vaginal Epithelial Cells
por: Webster, Paul, et al.
Publicado: (2020)

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175
por: Gallay, Philippe A., et al.
Publicado: (2016)

Clinical SARS-CoV-2 Kinetic Profiles Are Dependent on the Viral Strain and Host Vaccination Status
por: Gunawardana, Manjula, et al.
Publicado: (2022)

Clinical SARS-CoV-2 Kinetic Profiles Are Dependent on the Viral Strain and Host Vaccination Status
por: Gunawardana, Manjula, et al.
Publicado: (2022)

HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex Formation
por: Gawlik, Katarzyna, et al.
Publicado: (2014)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
por: Clark, Meredith R., et al.
Publicado: (2014)

Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting
por: Romano, Joseph W., et al.
Publicado: (2021)

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120
por: Binley, James M, et al.
Publicado: (2007)

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120
por: Binley, James M, et al.
Publicado: (2006)

Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice
por: Denton, Paul W, et al.
Publicado: (2008)

Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
por: Ewart, Gary, et al.
Publicado: (2023)

Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention
por: Liebenberg, Lenine J. P., et al.
Publicado: (2017)

The Development of Vaginal Microbicides for the Prevention of HIV Transmission
por: Weber, Jonathan, et al.
Publicado: (2005)

Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints
por: Gunawardana, Manjula, et al.
Publicado: (2021)

Beta- Lactam Antibiotics Stimulate Biofilm Formation in Non-Typeable Haemophilus influenzae by Up-Regulating Carbohydrate Metabolism
por: Wu, Siva, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0da8fdpuc4tr8q17ohe8aq46ka